- Home
- GLV vs NOTV Comparison
GLV vs NOTV Comparison
Compare GLV & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLV
- NOTV
- Stock Information
- Founded
- GLV 2004
- NOTV 1974
- Country
- GLV United States
- NOTV United States
- Employees
- GLV N/A
- NOTV N/A
- Industry
- GLV Finance/Investors Services
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- GLV Finance
- NOTV Health Care
- Exchange
- GLV Nasdaq
- NOTV Nasdaq
- Market Cap
- GLV 72.1M
- NOTV 57.7M
- IPO Year
- GLV N/A
- NOTV 1997
- Fundamental
- Price
- GLV $5.82
- NOTV $1.60
- Analyst Decision
- GLV
- NOTV Strong Buy
- Analyst Count
- GLV 0
- NOTV 1
- Target Price
- GLV N/A
- NOTV $5.00
- AVG Volume (30 Days)
- GLV 54.2K
- NOTV 391.8K
- Earning Date
- GLV 01-01-0001
- NOTV 08-06-2025
- Dividend Yield
- GLV 12.44%
- NOTV N/A
- EPS Growth
- GLV N/A
- NOTV N/A
- EPS
- GLV N/A
- NOTV N/A
- Revenue
- GLV N/A
- NOTV $505,299,000.00
- Revenue This Year
- GLV N/A
- NOTV $5.64
- Revenue Next Year
- GLV N/A
- NOTV $5.16
- P/E Ratio
- GLV N/A
- NOTV N/A
- Revenue Growth
- GLV N/A
- NOTV 0.85
- 52 Week Low
- GLV $4.70
- NOTV $1.15
- 52 Week High
- GLV $6.06
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- GLV 62.14
- NOTV 39.59
- Support Level
- GLV $5.72
- NOTV $1.56
- Resistance Level
- GLV $5.85
- NOTV $1.85
- Average True Range (ATR)
- GLV 0.06
- NOTV 0.11
- MACD
- GLV 0.01
- NOTV -0.01
- Stochastic Oscillator
- GLV 88.26
- NOTV 13.24
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.